Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s Laboratories Limited (NYSE:RDY) and Alvotech announced that they have entered into a ...

The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).

Dr Reddy’s Laboratories ( ($RDY) ) has issued an update. On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the ...

Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.